Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly.
Here are are a few highlights from this week:
- Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR (J Clin Oncol) - The long term analysis (median follow-up more than 4 years) of the CASTOR and POLLUX trials shows that daratumumab-based combinations induce higher rates of sustained MRD negativity versus standard of care, which are associated with durable remissions and prolonged clinical outcomes
- T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects (J Clin Oncol) - Discover cellular therapy other than CAR-T: In this clinical trial, durable complete remissions (> 3 years) were obtained in lymphoma patients with infusions of autologous T-cells targeting multiple tumor-associated antigens.
- Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL (Blood) - Both tumor-intrinsic and -extrinsic factors influence blinatumomab response: this analysis shows that CD19 mutations are commonly detected in CD19−neg relapse, and identifies a CD19-splice variant representing a new potential biomarker predictive of failure.
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies (Blood) - Is a second CAR-T cell infusion feasible and effective? According to the results presented in this paper, second CD19 CART2 infusions were feasible in CLL and NHL patients and induced responses in 39% of patients (CR, 20%).
You can access our complete resource library of scientific publications here.
Last Updated on Wednesday 10 February 2021.